Skye Bioscience Inc (SKYE) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Skye Bioscience Inc   (NASDAQ: SKYE)


Skye Bioscience Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Skye Bioscience Inc's ROI in the first quarter of 2026?
Skye Bioscience Inc recorded a cumulative net loss of $-57 million during 12 months ending in the first quarter of 2026, resulting in a negative return on investment (ROI) of -216.49%.

Within the Healthcare sector 764 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from 2963 to 4129.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM -61.73 % -47.22 % -10.91 % 69.31 % 303.67 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 9 20 33 44 59
Return On Investment (TTM) -216.49 % -143.04 % -100.1 % -68.44 % -47.19 %
SKYE's Overall Ranking # 4129 # 2963 # 0 # 3587 # 3538
Seq. Investment Change TTM -32.27 % -23.6 % -17.34 % -10.51 % -6.6 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -57 -56 -51 -42 -33

SKYE Company Profile >> Back to SKYE Roi Comparisons >> See Annual SKYE Return On Investment



Return On Investment SKYE's Ranking
Within: No.
Industry # 358
Sector # 765
Overall # 4129

Return On Investment Statistics
High Average Low
-35.86 %
-170.22 %
-686.64 %
(Dec 31 2024)   (Sep 30 2022)



  News about Skye Bioscience Inc Return on Investment ROI

Skye Bioscience: Navigating the Road Ahead with Phase 2 Data and Market Challenges

January 13, 2025

Skye Bioscience Inc. a trailblazer in the innovative realm of cannabinoid-based therapeutics, is gearing up for a significant year in 2025. As the company looks to unveil important Phase 2 clinical trial data related to its unique CB1 inhibitor for obesity, industry watchers are paying close attention. The anticipated results, expected in the second and fourth quarters of 2025, could serve as a critical inflection point not just for Skye but for the broader landscape of obesity treatments.In recent months, however, Skye s fiscal landscape has been less rosy. Over the past five trading days, shares of Skye Bioscience plummeted by 15.16%. This downturn is compounded by a staggering cumulative net loss of $42 million for the twelve months ending in the third quarter of 2024. Consequently, the company reported a disheartening return on investment (ROI) of -72.71% during this period. These figures underscore a challenging environment for Skye Bioscience as it strives to carve out a niche in a competitive healthcare market.





Financial Statements
Skye Bioscience Inc's I. Quarter Investments $ 9 Millions SKYE's Balance sheet
Skye Bioscience Inc's I. Quarter Income $ -13 Millions Quarterly SKYE's Income Statement
SKYE's Income by Division See SKYE's Income by Division


SKYE Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 20 68 -3 6 1
Y / Y Investment Growth -70.61 % - - 515.45 % -
Net Income in Millions -56 -27 -19 -9 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -278.12 % -38.83 % - -134.97 % -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SKYE's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SKYE's Competitors
Subscribers only: Roi for Skye Bioscience Inc's Suppliers
Subscribers only: Return On Investment for SKYE's Customers

Other Ratios
SKYE's Roa SKYE's Inventory Turnover Ratio SKYE's Growth Rates SKYE's Dividend Statistics
SKYE's Profitability Ratios SKYE's Asset Turnover Ratio SKYE's Dividend Growth
SKYE's Roe SKYE's Valuation Ratios SKYE's Financial Strength Ratios SKYE's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:12:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.